{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05680922","nct_id":"NCT05680922","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05680922. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)","label":"Experimental LB2102","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer Extensive Stage","Large Cell Neuroendocrine Carcinoma of the Lung"],"enrollment":{"count":41,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LB2102","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-03-24","lead_sponsor":"Legend Biotech USA Inc","official_title":"A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)","timeFrame":"28 days"},{"measure":"To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)","timeFrame":"90 days"}],"references":[{"citation":"Williams CM, Arnold SM, Villano JL, Alonso ENA, Brainson CF, Schwarzenberger PO, Vahora S, Qasrawi A, Munker R, Evers BM, Hao Z. Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report. Front Oncol. 2026 Jul 7;16:1885732. doi: 10.3389/fonc.2026.1885732. eCollection 2026.","pmid":"42482749","type":"DERIVED"},{"citation":"Ouyang W, Xu Z, Guan S, Hu Y, Gou X, Liu Z, Guo W, Huang Y, Zhang L, Zhang X, Li T, Yang B. Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. Int J Biol Sci. 2025 Jan 20;21(3):1322-1341. doi: 10.7150/ijbs.105973. eCollection 2025.","pmid":"39897044","type":"DERIVED"}],"start_date":{"date":"2023-07-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05680922"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05680922"}